DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ofatumumab
Drug: First line DMT

First Posted Date: 2021-03-09

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT04788615

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia

Phase 1

Terminated

Conditions: Amblyopia

Interventions: Device: Patching of the sound eye
Device: Binocular video games

First Posted Date: 2021-03-05

Last Posted Date: 2023-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT04784390

Locations: 🇨🇦
Novartis Investigative Site, Waterloo, Ontario, Canada

Special Drug Use Surveillance for Entresto Tablets

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: Entresto

First Posted Date: 2021-03-04

Last Posted Date: 2023-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 688

Registration Number: NCT04781881

Locations: 🇯🇵
Novartis Investigative Site, Yamaguchi, Japan

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Phase 4

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Brolucizumab

First Posted Date: 2021-03-01

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT04774926

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Phase 1

Completed

Conditions: Hyperlipidemia

Interventions: Drug: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
Drug: Placebo
Drug: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)

First Posted Date: 2021-02-26

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04774003

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056

Phase 1

Withdrawn

Conditions: Cocaine Use Disorder

Interventions: Drug: Placebo
Drug: AFQ056

First Posted Date: 2021-02-25

Last Posted Date: 2021-07-01

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04771143

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: inclisiran sodium
Drug: Placebo

First Posted Date: 2021-02-21

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 345

Registration Number: NCT04765657

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Terminated

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Interventions: Drug: Brolucizumab

First Posted Date: 2021-02-21

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT04764656

Locations: 🇵🇹
Novartis Investigative Site, Tomar, Portugal

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Iptacopan

First Posted Date: 2021-02-10

Last Posted Date: 2025-03-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT04747613

Locations: 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Univ of California Irvine (Chao Family Comprehensive Cancer Center), Orange, California, United States

and more 6 locations

Managed Access Programs for INC424, Ruxolitinib

Conditions: Primary Myelofibrosis (PMF)
Post Polycythemia Myelofibrosis (PPV MF)
Thrombocythemia Myelofibrosis (PET-MF)
Severe/very Severe COVID-19 Illness
Polycythemia Vera (PV)
Steroid Refractory Acute Graft Versus Host Disease (SR AGVHD)
Steroid Refractory Chronic Graft Versus Host Disease (SR CGVHD)

First Posted Date: 2021-02-09

Last Posted Date: 2025-01-16

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04745637

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy